Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-21

Study Completion Date

2021-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT06296966

Dry Eye

RECRUITING PHASE2

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055

Dry Eye

RECRUITING PHASE2

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543

Allergic Conjunctivitis

COMPLETED PHASE3

Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

NCT00241319

Allergic Conjunctivitis

COMPLETED PHASE3

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951

Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VSJ-110 Solution

Group Type EXPERIMENTAL

VSJ-110

Intervention Type DRUG

ophthalmic solution

Placebo Solution

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

ophthalmic solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VSJ-110

ophthalmic solution

Intervention Type DRUG

Placebo

ophthalmic solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years of age of either gender and any race
* Able to provide written informed consent and sign the HIPAA form
* Willing and able to follow all instructions and attend all study visits